Laetrile and Claims of a Suppressed Cancer Cure

The claim and its context

Laetrile, often called amygdalin or “vitamin B17,” has been promoted as a cancer cure supposedly suppressed by medical institutions. NCI-reviewed human evidence did not show meaningful antitumor benefit, and cyanide poisoning is a documented hazard. Legal disputes over access and regulation do not establish that an effective cure was hidden.

Historical chronology

Laetrile was promoted in the mid-20th century, and its use became a political and legal controversy in the 1970s. At the National Cancer Institute’s request, investigators assessed clinical outcomes in patients receiving the compound. The FDA has not approved it as a cancer treatment.

What the record establishes

The NCI-sponsored clinical study reported no substantive benefit in the studied patients and noted cyanide toxicity. The study was not a modern randomized trial and had limitations, but its negative results align with the absence of convincing clinical efficacy. Amygdalin can release cyanide, and oral use is especially concerning.

Clinical and scientific context

A proposed biochemical mechanism or laboratory effect does not establish that a treatment improves survival or quality of life in people. Cancer treatments require controlled clinical outcomes and safety monitoring. Cyanide interferes with cellular oxygen use and can cause severe poisoning; this dossier is not treatment guidance, and laetrile should not replace evidence-based cancer care.

Counterevidence, uncertainty, and calibration

The clinical evidence base is limited, so it cannot answer every theoretical question about every formulation. But no credible human evidence supports a cure claim, while toxicity is mechanistically plausible and observed. Regulatory disagreement, patient advocacy, and past access litigation are not evidence of a suppressed effective therapy.

What could change the assessment

A preregistered, ethically reviewed clinical trial with a defined product, adequate controls, clinically meaningful outcomes, and independent replication could change the efficacy assessment. In vitro results or testimonials alone would not establish benefit.

Source notes and limitations

1. National Cancer Institute — Laetrile/Amygdalin (PDQ®)Evidence summary covering human studies, lack of demonstrated benefit, and cyanide risks; periodically updated and not individualized medical advice.
2. Moertel et al. — A Clinical Trial of Amygdalin (Laetrile) in the Treatment of Human Cancer, New England Journal of Medicine (1982)Primary clinical study of treated patients; its design limits broad efficacy inference but found no substantive benefit.
3. National Center for Complementary and Integrative Health — Cancer and Complementary Health ApproachesEvidence-focused overview stressing that unproven approaches should not replace or delay cancer treatment; not a laetrile-specific trial.